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R. Cody: It has been shown that digoxin lowers plasma 
renin activity by directly suppressing renin release, rather 
than by a hemodynamic effect. Conversely, calcium antag- 
onists may directly stimulate the release of renin but will 
directly suppress the release of aldosterone from the adrenal 
gland. In view of these actions, it will be interesting tosee 
the effect of calcium antagonists in ongoing studies of 
patients with heart failure. In Dr. Packer’s tudy of amlo- 
dipine, most patients were also receiving angiotensin- 
converting enzyme inhibitors. Would amlodipine xert a 
favorable tfect in the absence ofbackground therapy with a 
converting enzyme inhibitor? 
M. Packer: In our study of amiodipine inheart failure, the 
number of patients not receiving treatment with a converting 
enzyme inhibitor was too small to permit definitive conclu- 
sions. 
M. Sole: Drs. Packer and Elkayam, what is the evidence 
that verapamil or diltiazem administration results in neuro- 
hormonal ctivation? I agree that the dihydropyridines stim- 
ulate neurohormonal systems, but I do not think such data 
exist for the phenylalkylamines or the henzothiazepines. 
How does amlodipine compare with these agents? 
U. EIkayam: We have the only data published regarding 
this question. In a short-term study of single doses of 60 and 
90 mg of diltiazem, we found no effect on circulating 
neurohormones. 
J. Cohn: We also found no neurohormonal stimulation 
with nitrendipine inpatients with heart failure: There was no 
change in plasma renin activity and plasma norepinephrine 
actually decreased. Yet that measurement may not be a good 
marker for neurohormonal activation. 
M. packer: 1 agree with Dr. Cohn on that point. Although 
we were impressed by the decrease in circulating norepi- 
ncphrine produced by amlodipine in our study, such a 
finding does not necessarily mean that there was a decline in 
the activity of the sympathetic nervous ystem. It is possible 
that he decline in plasma norepinephrine was related to an 
increased clearance ofnorepinephrine that resulted from the 
hemodynamic improvement produced by amlodipine. 
M. ‘I’hames: It is important to be cautious about he 
interpretation f neurohumoral esponses that may occur 
after administration f agents such as calcium channel block- 
ers. When these agents (particularly the dihydropyridine 
derivatives) are administered to normal subjects, they can 
cause neuronumoral excitation, as a result of refIex mecha- 
nisms as well as other factors. However, in patients with 
heart failure, the effect of a calcium channel antagonist will 
depend on the degree to which those rellexes are impaired 
and whether or not the drug worsens the degree of heart 
failure. G’ven this interplay, itis difficult o predict what he 
effect of a calcium channel blocker on neurohormonal sys- 
tems will be. Both worsening heart failure and reflex excita- 
tion can cause nourohormonal activation. 
U. Elkayam: Dr. Cody suggests that nemohormonal 
changes seen with calcium antagonists are not necessarily 
related to their hemodynamic effect but represent a diict 
effect caused by the removal of the inhiiitory effect of 
calcium on renin release. All calcium channel blockers 
increase plasma renin activity, but tbe amlodipine study 
never eported the effect of the drug on the renin-angiotensin 
system. 
M. packer: We never reported the changes in plasma 
renin activity in our amlodipine study because of the very 
high proportion ofpatients who were treated with a convert- 
ing enzyme inhibitor. 
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